A Peptide-Fc Opsonin with Pan-Amyloid Reactivity
暂无分享,去创建一个
Alan Stuckey | Jonathan S. Wall | S. Kennel | J. S. Foster | T. Richey | J. Wall | Tina Richey | Stephen J. Kennel | A. Stuckey | James S. Foster | S. Macy | Angela D. Williams | Richa Koul-Tiwari | Emily B. Martin | Sallie Macy | Daniel Craig Wooliver | D. C. Wooliver | Richa Koul-Tiwari | Tina Richey
[1] Qian Peng,et al. Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth , 2016, Oncotarget.
[2] S. Kennel,et al. Phagocyte depletion inhibits AA amyloid accumulation in AEF-induced huIL-6 transgenic mice , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[3] V. Algalarrondo,et al. TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies , 2016, Expert opinion on pharmacotherapy.
[4] S. Gordon,et al. Multinucleated Giant Cells Are Specialized for Complement-Mediated Phagocytosis and Large Target Destruction , 2015, Cell reports.
[5] M. Beggs,et al. Prevalence and organ distribution of leukocyte chemotactic factor 2 amyloidosis (ALECT2) among decedents in New Mexico , 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[6] S. Nasr,et al. Leukocyte Cell-Derived Chemotaxin 2-Associated Amyloidosis: A Recently Recognized Disease with Distinct Clinicopathologic Characteristics. , 2015, Clinical journal of the American Society of Nephrology : CJASN.
[7] Alan Stuckey,et al. Preliminary characterization of a novel peptide-Fc-fusion construct for targeting amyloid deposits , 2017, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[8] P. Westermark,et al. Amyloidogenic potential of foie gras , 2007, Proceedings of the National Academy of Sciences.
[9] M. Liedtke,et al. First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Gertz,et al. Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid‐directed monoclonal antibody , 2016, American journal of hematology.
[11] A. Dispenzieri,et al. What do I need to know about immunoglobulin light chain (AL) amyloidosis? , 2012, Blood reviews.
[12] G. Himmler,et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. , 2010, Protein engineering, design & selection : PEDS.
[13] J. Cather,et al. Etanercept: An overview. , 2003, Journal of the American Academy of Dermatology.
[14] Roy Jefferis,et al. Glycosylation as a strategy to improve antibody-based therapeutics , 2009, Nature Reviews Drug Discovery.
[15] S. Akilesh,et al. FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.
[16] S. Jung,et al. The Highly Evolvable Antibody Fc Domain. , 2016, Trends in biotechnology.
[17] S. Kennel,et al. Specific Amyloid Binding of Polybasic Peptides In Vivo Is Retained by β-Sheet Conformers but Lost in the Disrupted Coil and All D-Amino Acid Variants , 2017, Molecular Imaging and Biology.
[18] M. Pepys. Pathogenesis, diagnosis and treatment of systemic amyloidosis. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[19] Zuben E Sauna,et al. Fc fusion as a platform technology: potential for modulating immunogenicity. , 2015, Trends in biotechnology.
[20] F. Crozet,et al. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody , 2014, mAbs.
[21] N. Porksen,et al. Engineering and characterization of the long‐acting glucagon‐like peptide‐1 analogue LY2189265, an Fc fusion protein , 2010, Diabetes/metabolism research and reviews.
[22] C. Niemietz,et al. Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis , 2015, Molecules.
[23] S. Kennel,et al. Dynamic PET and SPECT imaging with radioiodinated, amyloid-reactive peptide p5 in mice: A positive role for peptide dehalogenation , 2014, Peptides.
[24] M. Fändrich,et al. AA amyloidosis: pathogenesis and targeted therapy. , 2015, Annual review of pathology.
[25] R. Falk,et al. Current perspectives on cardiac amyloidosis. , 2012, American journal of physiology. Heart and circulatory physiology.
[26] E. Uberbacher,et al. Preclinical Validation of the Heparin-Reactive Peptide p5+14 as a Molecular Imaging Agent for Visceral Amyloidosis , 2015, Molecules.
[27] G. Westermark,et al. AA-Amyloid is cleared by endogenous immunological mechanisms , 2012, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[28] A. Dispenzieri,et al. Immunoglobulin Light Chain Systemic Amyloidosis. , 2016, Cancer treatment and research.
[29] M. Pras,et al. The characterization of soluble amyloid prepared in water. , 1968, The Journal of clinical investigation.
[30] S. Kennel,et al. Secondary structure propensity and chirality of the amyloidophilic peptide p5 and its analogues impacts ligand binding - In vitro characterization , 2016, Biochemistry and biophysics reports.
[31] S. Kennel,et al. In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides , 2011, Proceedings of the National Academy of Sciences.
[32] M. Maurer,et al. Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis , 2017, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[33] M. Sanford. Dulaglutide: First Global Approval , 2014, Drugs.
[34] R. Kisilevsky. Preparation and propagation of amyloid-enhancing factor. , 2005, Methods in molecular biology.
[35] S. Kennel,et al. Comparative Analysis of Peptide p5 and Serum Amyloid P Component for Imaging AA Amyloid in Mice Using Dual-Isotope SPECT , 2012, Molecular Imaging and Biology.
[36] S. Kennel,et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. , 2010, Blood.
[37] S. Kennel,et al. A Binding-Site Barrier Affects Imaging Efficiency of High Affinity Amyloid-Reactive Peptide Radiotracers In Vivo , 2013, PloS one.
[38] A. Petrie,et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis , 2010, British journal of haematology.
[39] Steven M. Johnson,et al. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. , 2012, Journal of molecular biology.
[40] J. L. Leonard,et al. Localization of type I iodothyronine 5'-deiodinase to the basolateral plasma membrane in renal cortical epithelial cells. , 1991, The Journal of biological chemistry.
[41] Søren L Pedersen,et al. Half‐Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation , 2016, ChemMedChem.
[42] P. Mahadevan,et al. An overview , 2007, Journal of Biosciences.
[43] R. Kontermann,et al. Pharmacokinetic properties of IgG and various Fc fusion proteins in mice , 2016, mAbs.
[44] F. Gao,et al. Transient expression of an IL-23R extracellular domain Fc fusion protein in CHO vs. HEK cells results in improved plasma exposure. , 2010, Protein expression and purification.
[45] M. Schell,et al. Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. , 1999, Biochemistry.
[46] J. Dumont,et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics , 2015, Critical reviews in biotechnology.
[47] J. Moon,et al. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. , 2015, The New England journal of medicine.
[48] P. Dolan,et al. 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis † , 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[49] P. Westermark,et al. Acceleration of amyloid protein A amyloidosis by amyloid-like synthetic fibrils. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[50] P. Hawkins,et al. New and developing therapies for AL amyloidosis , 2017, Expert opinion on pharmacotherapy.
[51] D. Kirschner,et al. A bacteriophage capsid protein provides a general amyloid interaction motif (GAIM) that binds and remodels misfolded protein assemblies. , 2014, Journal of molecular biology.
[52] S. Kennel,et al. Comparative evaluation of p5+14 with SAP and peptide p5 by dual-energy SPECT imaging of mice with AA amyloidosis , 2016, Scientific Reports.
[53] Benjamin Wu,et al. Pharmacokinetics of Peptide-Fc fusion proteins. , 2014, Journal of pharmaceutical sciences.